Kura Oncology, Inc. (NASDAQ:KURA) Stock Has Consensus Price Target of $25.35

Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $25.35.

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Wednesday, October 14th. Wedbush increased their price objective on Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, August 24th. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a research note on Monday, August 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, October 15th.

Kura Oncology News Roundup

Here’s some of the latest news about KURA:

• Positive Sentiment: Kura reported a Q3 loss of $0.78 per share, narrower than analyst estimates of about $0.82–$0.83 and the year-ago loss of $0.85. Zacks Q3 results
• Positive Sentiment: KOMZIFTI net product revenue rose 53% sequentially to $13.9 million. New patient starts increased 30%, prescriptions grew 65%, and the drug held a majority share of new starts in its market—evidence of expanding commercial uptake. Company results and update
• Negative Sentiment: Quarterly revenue of $22.84 million was below analyst expectations of $24.94 million, a shortfall that tempers the positive sales-growth news. Q3 loss narrows, revenue rises

Insider Activity at Kura Oncology

In related news, insider Francis Burrows sold 20,726 shares of Kura Oncology stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $10.83, for a total value of $224,462.58. Following the completion of the sale, the insider owned 42,327 shares of the company’s stock, valued at approximately $458,401.41. The trade was a 32.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mollie Leoni sold 28,802 shares of the company’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total transaction of $309,621.50. Following the completion of the sale, the insider owned 141,095 shares of the company’s stock, valued at $1,516,771.25. This represents a 16.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 153,881 shares of company stock worth $1,708,183 over the last quarter. 7.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently bought and sold shares of the business. IFP Advisors Inc boosted its holdings in shares of Kura Oncology by 136.5% during the 2nd quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after buying an additional 1,467 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Kura Oncology by 14.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,232 shares of the company’s stock worth $175,000 after acquiring an additional 2,104 shares during the period. Allspring Global Investments Holdings LLC increased its position in Kura Oncology by 11.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company’s stock worth $194,000 after acquiring an additional 2,304 shares during the period. Sterling Capital Management LLC increased its position in Kura Oncology by 842.5% during the third quarter. Sterling Capital Management LLC now owns 2,818 shares of the company’s stock worth $30,000 after acquiring an additional 2,519 shares during the period. Finally, Pictet Asset Management Holding SA raised its stake in Kura Oncology by 22.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 14,412 shares of the company’s stock valued at $154,000 after purchasing an additional 2,656 shares during the last quarter.

Kura Oncology Stock Up 2.1%

Shares of NASDAQ:KURA opened at $7.73 on Thursday. The company has a current ratio of 4.73, a quick ratio of 4.71 and a debt-to-equity ratio of 0.12. Kura Oncology has a 1 year low of $6.75 and a 1 year high of $13.90. The business has a fifty day simple moving average of $10.39 and a 200 day simple moving average of $9.78.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.04. Kura Oncology had a negative return on equity of 265.89% and a negative net margin of 369.26%. The firm had revenue of $22.84 million during the quarter, compared to analysts’ expectations of $24.94 million. On average, equities research analysts expect that Kura Oncology will post -3.25 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.